As of now, various clinical trials have evidenced the effectiveness of radiomics in all stages of neurosurgical treatment of brain tumors, be it preoperatively (e.g., for key mutation detection, including those in IDH1, IDH2 genes, and 1p/19q chromosomal codeletion) [16,17], intraoperatively (e.g., for detection of tumor cells among healthy tissues) [18], or postoperatively (e.g., for discrimination of tumor recurrence from pseudoprogression) [19,20]. The gene discussed is IDH2; the disease is neoplasm.